IKA PUBLICATIONS & ABSTRACTS
Clinical evidence from IKA
Evidence / Endocrine / IKA
IKA Trial: MammaPrint UltraLow & Limited Systemic Endocrine Overtreatment
IKA Trial, Breast Cancer Res Treat, 2022; 194(2): 265-278 Authors: Opdam, et al.
Read More
Contact
For the US, Puerto Rico, Canada
and South America
Agendia Inc. USA, 22 Morgan, Irvine, CA 92618
(888) 321-2732
customercare@agendia.com
For outside the Americas
Agendia NV, Radarweg 60, 1043 NT Amsterdam, The Netherlands
+31 (0)20 462 1510
customerservice@agendia.com
©2024 Agendia. All rights reserved. MammaPrint and Blueprint are registered trademarks of Agendia, Inc.
